Baseline characteristics of the patients in the estimation and validation cohorts
| Variable | All patients (n=506) | Estimation cohort (n=253) | Validation cohort (n=253) | p Value |
|---|---|---|---|---|
| Age (years) | 37.45±9.6 | 37.51±10.0 | 37.39±9.1 | 0.886 |
| Male, n (%) | 337 (66.6) | 166 (65.6) | 171 (68.0) | 0.637* |
| BMI (kg/m2) | 22.5±3.51 | 22.5±3.60 | 22.5±3.49 | 0.957 |
| WCC (109/L) | 5.51±1.60 | 5.47±1.61 | 5.55±1.49 | 0.558 |
| RBC (1012/L) | 4.81±0.51 | 4.80±0.52 | 4.81±0.50 | 0.817 |
| Hgb (g/L) | 148±18 | 147±19 | 148±17 | 0.501 |
| RDW (%) | 13.0±1.0 | 13.1±1.2 | 13.0±0.8 | 0.092 |
| PLT (109/L) | 178±53 | 181±55 | 175±51 | 0.191 |
| TP (g/L) | 72.2±6.7 | 72.5±6.7 | 71.8±6.7 | 0.268 |
| ALB (g/L) | 45.4±5.2 | 45.2±5.2 | 45.6±5.1 | 0.482 |
| TBIL (μmol/L) | 13 (3–436) | 13 (4–436) | 14 (3–280) | 0.748† |
| AST (U/L) | 30 (14–479) | 31 (14–479) | 30 (14–358) | 0.478† |
| ALT (U/L) | 40 (8–631) | 45 (8–569) | 38 (10–631) | 0.019† |
| GGT (U/L) | 25 (6–586) | 25 (7–586) | 25 (6–456) | 0.653† |
| ALP (U/L) | 68 (22–292) | 68 (29–184) | 69 (22–292) | 0.871† |
| FPG (mmol/L) | 4.72±1.41 | 4.64±0.90 | 4.80±1.80 | 0.268 |
| TG (mmol/L) | 0.97 (0.38–9.41) | 0.99 (0.39–9.41) | 0.94 (0.38–7.67) | 0.780† |
| Tch (mmol/L) | 4.47±1.04 | 4.46±1.03 | 4.47±1.05 | 0.917 |
| PT (s) | 11.8±1.6 | 11.8±2.1 | 11.8±0.9 | 0.752 |
| APTT (s) | 28.2±4.8 | 28.2±5.4 | 28.2±4.2 | 0.952 |
| Fbg (g/L) | 2.31±0.61 | 2.31±0.64 | 2.31±0.57 | 0.918 |
| AFP (ng/mL) | 3.4 (0.8–644.3) | 3.4 (0.8–644.3) | 3.4 (1.1–259.8) | 0.811† |
| HBeAg status, n (%) | 285 (56.3) | 142 (56.1) | 143 (56.5) | 0.929* |
| HBV DNA detectable (%) | 351 (69.4) | 182 (71.9) | 169 (66.8) | 0.210* |
| Anti-HBV therapy (%) | 47 (9.3) | 23 (9.1) | 24 (9.5) | 0.878* |
| Fibrosis stage, n (%) | 0.933* | |||
| S0 | 251 (49.6) | 123 (48.6) | 128 (50.6) | |
| S1 | 167 (33.0) | 84 (33.2) | 83 (32.8) | |
| S2 | 48 (9.5) | 26 (10.2) | 22 (8.7) | |
| S3 | 22 (4.3) | 10 (4.0) | 12 (4.7) | |
| S4 | 18 (3.6) | 10 (4.0) | 8 (3.2) |
*p Values are comparisons between the estimation and validation cohorts using an independent samples t test, except using the χ2 test.
†p Values are comparisons between the estimation and validation cohorts using an independent samples t test, except using the Mann-Whitney U test.
AFP, α-fetal protein; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BMI, body mass index; Fbg, fibrinogen; FPG, fasting plasma glucose; GGT, γ-glutamyl transpeptidase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; Hgb, haemoglobin; PLT, platelet count; PT, prothrombin time; RBC, red blood cell; RDW, red cell distribution width; TBIL, total bilirubin; Tch, total cholesterol; TG, triglyceride; TP, total protein; WCC, white cell count.